Skip to main content

CITADEL ADVISORS LLC

Position in NVCT — Nuvectis Pharma, Inc.

CIK 1423053 MIAMI, FL

Position in NVCT

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$606,225
+$606,225 QoQ
Shares Held
78,425
Ownership
0.296%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2022
8 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVCT Over Time

Shares Held

Position Value (USD)

Derivatives in NVCT

reported options exposure · as of Dec 31, 2025
CallValue
$581,350
CallShares
77,000
PutValue
$109,475
PutShares
14,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. NVCT ranks #253 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in NVCT

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $606,225 78,425
2025-12-31 $581,350 77,000
2025-12-31 $109,475 14,500
2025-09-30 $525,546 87,300
2025-06-30 $169,569 22,700
2025-03-31 $109,424 11,200
2025-03-31 $101,060 10,344
2025-03-31 $420,110 43,000
2024-06-30 $94,551 14,937
2023-06-30 $447,607 28,028
2022-06-30 $392,772 35,069